Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial

Study limitation reported by the research below: “The open-label extension data (7 weeks) are not reported in the abstract; longer-term outcomes are unknown.”